Effective filtration area of 3.9 cm² with a 25 mm size! Proven track record with the fully automatic dissolution testing system manufactured by Dai Nippon Seiki.
We would like to introduce the "0.45 μm PSF Acrodisc Syringe Filter" for HPLC and IC handled by Nippon Paul Co., Ltd. The filtration efficiency is improved by the multi-prefilter (GxF), allowing for a filtration volume that is 2 to 4 times greater than that of standard glass fiber products. Additionally, it has high pressure resistance, eliminating concerns about housing breakage during use. 【Features】 ■ Wide range of product lineup - HPLC guaranteed: GHP, PVDF, Nylon, PTFE - IC guaranteed: Supor (PES) ■ Column protection ■ Low drug adsorption and low elution performance *For more details, please refer to the PDF document or feel free to contact us.
Inquire About This Product
Related Videos
basic information
【Other Features】 - Increased filtration efficiency with the multi-prefilter (GxF), achieving 2 to 4 times the filtration amount of standard fiberglass products. - Effective filtration area of 3.9 cm² with a size of 25 mm. - Housing made of low-adhesion polypropylene. - High pressure resistance, eliminating concerns about housing destruction during use. - Compatibility guaranteed for SOTAX automatic analyzers for elution testing. - Long-standing track record with fully automatic elution testing systems from Dainippon Seiki. *For more details, please refer to the PDF document or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
【Usage】 ■ For sample pretreatment ■ For HPLC and IC *For more details, please refer to the PDF document or feel free to contact us.
Company information
Cytiva and Pall Life Sciences have merged their businesses and will officially launch under the "Cytiva" brand on May 1, 2023. Under our mission of "Advancing therapies, faster," we will integrate both organizations and focus even more on supporting the development and manufacturing of better therapies for patients as a stronger global provider of technologies and services. The new Cytiva will offer a broader and deeper expertise and a rich lineup of products and services to better support various customers involved in research and the manufacturing and development of biopharmaceuticals, enabling them to deliver therapies to patients more quickly, from discovery to delivery. With a rich history spanning several hundred years, Pall Life Sciences and Cytiva, as part of the Danaher Group, will continue to unite to provide better services to our customers.